CD8A and neoplasm: When used in combination with adoptive transfer of activated, anti-tumor effector CD8+ T cells, MC-TG, but not free TG, could significantly improve therapeutic outcome by depleting suppressive MDSCs, thus allowing the T cells to be more effective in the tumor microenvironment.